Rising diabetes awareness activities and expanding healthcare access are creating opportunities for GLP-1 drug adoption across healthcare providers, pharmaceutical distributors, and telemedicine platforms in major Indian healthcare regions
A., Jensen, N
If you are overweight, specifically having increased visceral adiposity, you are diabetic or you have pre-diabetes, again, go back to the insulin, uh, show
Despite their exploding popularity, the current GLP-1 injections (semaglutide though is also orally available) face accessibility issues due to cost and adverse effects and thus the next big move for the space, an easy to - pop pill could be lucrative, for which clinical trials are already well underway
Brietzke E, Kapczinski F, Grassi-Oliveira R, Grande I, Vieta E, McIntyre RS
The no-DAC version has a shorter half-life, producing a research profile that mimics natural GH pulses rather than sustained elevation, which is preferred for studies requiring a more controlled release pattern
